ATE507828T1 - Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung - Google Patents

Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung

Info

Publication number
ATE507828T1
ATE507828T1 AT02751609T AT02751609T ATE507828T1 AT E507828 T1 ATE507828 T1 AT E507828T1 AT 02751609 T AT02751609 T AT 02751609T AT 02751609 T AT02751609 T AT 02751609T AT E507828 T1 ATE507828 T1 AT E507828T1
Authority
AT
Austria
Prior art keywords
hypocholesteric
hypolipidemic
activity
preparation
pharmaceutical compositions
Prior art date
Application number
AT02751609T
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Vidya Bhushan Lohray
Vijay Kumar Barot
Saurin Khimshankar Raval
Preeti Saurin Raval
Sujay Basu
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Application granted granted Critical
Publication of ATE507828T1 publication Critical patent/ATE507828T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G5/00—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators
    • G09G5/36—Control arrangements or circuits for visual indicators common to cathode-ray tube indicators and other visual indicators characterised by the display of a graphic pattern, e.g. using an all-points-addressable [APA] memory
    • G09G5/363—Graphics controllers
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F3/00—Input arrangements for transferring data to be processed into a form capable of being handled by the computer; Output arrangements for transferring data from processing unit to output unit, e.g. interface arrangements
    • G06F3/14—Digital output to display device ; Cooperation and interconnection of the display device with other functional units
    • G06F3/1423—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display
    • G06F3/1438—Digital output to display device ; Cooperation and interconnection of the display device with other functional units controlling a plurality of local displays, e.g. CRT and flat panel display using more than one graphics controller
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09G—ARRANGEMENTS OR CIRCUITS FOR CONTROL OF INDICATING DEVICES USING STATIC MEANS TO PRESENT VARIABLE INFORMATION
    • G09G2360/00—Aspects of the architecture of display systems
    • G09G2360/12—Frame memory handling
    • G09G2360/122—Tiling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Human Computer Interaction (AREA)
  • Computer Hardware Design (AREA)
  • Neurosurgery (AREA)
  • Computer Graphics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
AT02751609T 2001-07-26 2002-07-25 Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung ATE507828T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN711MU2001 2001-07-26
PCT/IN2002/000155 WO2003009841A1 (en) 2001-07-26 2002-07-25 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine

Publications (1)

Publication Number Publication Date
ATE507828T1 true ATE507828T1 (de) 2011-05-15

Family

ID=11097270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02751609T ATE507828T1 (de) 2001-07-26 2002-07-25 Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung

Country Status (31)

Country Link
US (6) US6987123B2 (de)
EP (1) EP1414439B1 (de)
JP (2) JP4313194B2 (de)
KR (2) KR20060094545A (de)
CN (1) CN100450477C (de)
AP (1) AP1808A (de)
AR (1) AR036347A1 (de)
AT (1) ATE507828T1 (de)
AU (1) AU2002355205B2 (de)
BR (1) BRPI0211665B8 (de)
CA (1) CA2454863C (de)
CO (1) CO5390079A1 (de)
CY (1) CY1111876T1 (de)
DE (1) DE60239939D1 (de)
DK (1) DK1414439T3 (de)
EA (1) EA006858B1 (de)
ES (1) ES2366279T3 (de)
HR (1) HRP20040138B1 (de)
IL (1) IL160042A (de)
MX (1) MXPA04000758A (de)
MY (1) MY140057A (de)
NO (1) NO326698B1 (de)
NZ (2) NZ545896A (de)
OA (1) OA12702A (de)
PL (1) PL224397B1 (de)
PT (1) PT1414439E (de)
RS (1) RS51837B (de)
SI (1) SI1414439T1 (de)
UA (1) UA76992C2 (de)
WO (1) WO2003009841A1 (de)
ZA (1) ZA200400563B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US20040047919A1 (en) * 2002-06-13 2004-03-11 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
US20050288373A1 (en) * 2002-10-24 2005-12-29 Ron Eyal S Methods of treating various conditions by administration of sustained release L-arginine
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
EP1636183A1 (de) * 2003-05-16 2006-03-22 Ambit Biosciences Corporation Pyrrolverbindungen und deren verwendung
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
US7744817B2 (en) * 2003-08-11 2010-06-29 Sakura Finetek U.S.A., Inc. Manifold assembly
US7767152B2 (en) * 2003-08-11 2010-08-03 Sakura Finetek U.S.A., Inc. Reagent container and slide reaction retaining tray, and method of operation
US9518899B2 (en) * 2003-08-11 2016-12-13 Sakura Finetek U.S.A., Inc. Automated reagent dispensing system and method of operation
PT1773768T (pt) * 2004-07-30 2018-11-30 Exelixis Inc Derivados de pirrol como agentes farmacêuticos
US20110092566A1 (en) * 2004-11-19 2011-04-21 Srivastava Satish K Treatment of cancer with aldose reductase inhibitors
WO2007095603A2 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
CN103554095A (zh) * 2006-02-15 2014-02-05 Abbvie公司 新的乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
US8459509B2 (en) 2006-05-25 2013-06-11 Sakura Finetek U.S.A., Inc. Fluid dispensing apparatus
EP2139330B1 (de) * 2007-03-23 2014-09-24 The Board of Regents of The University of Texas System Verfahren mit aldose-reduktase-inhibitoren
US20090270490A1 (en) * 2008-04-24 2009-10-29 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibition
MX354133B (es) 2010-08-18 2018-02-14 Samumed Llc Dicetonas e hidroxicetonas como activadores de la trayectoria de señalizacion de catenina.
AU2015258299B2 (en) * 2010-08-18 2017-10-19 Samumed, Llc Diketones and hydroxyketones as catenin signaling pathway activators
AU2015268725B2 (en) * 2011-01-31 2016-10-20 Zydus Lifesciences Limited Treatment for lipodystrophy
JP2014504610A (ja) * 2011-01-31 2014-02-24 カディラ ヘルスケア リミテッド 脂肪異栄養症の処置
US8752732B2 (en) 2011-02-01 2014-06-17 Sakura Finetek U.S.A., Inc. Fluid dispensing system
JP5971657B2 (ja) * 2011-04-20 2016-08-17 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
US8932543B2 (en) 2011-09-21 2015-01-13 Sakura Finetek U.S.A., Inc. Automated staining system and reaction chamber
US8580568B2 (en) 2011-09-21 2013-11-12 Sakura Finetek U.S.A., Inc. Traceability for automated staining system
US8754084B2 (en) 2012-03-27 2014-06-17 The Board Of Trustees Of The University Of Illinois Therapeutic methods and agents for treating myotonic dystrophy
EP3456325A3 (de) 2013-02-22 2019-05-22 Samumed, LLC Gamma-diketone als wnt/beta-catenin-signalisierungspfadaktivatoren
US20160166539A1 (en) 2013-04-22 2016-06-16 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
ES2889916T3 (es) 2013-05-30 2022-01-14 Cadila Healthcare Ltd Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
TW201636015A (zh) * 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (de) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
IN2013MU02905A (de) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
US9376421B2 (en) 2014-08-08 2016-06-28 The Board Of Trustees Of The University Of Illinois Compounds and methods for myotonic dystrophy therapy
SI3206686T1 (sl) 2014-08-20 2020-03-31 Samumed, Llc Gama-diketoni za zdravljenje in preprečevanje staranja kože in gub
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2018104916A1 (en) 2016-12-09 2018-06-14 Cadila Healthcare Limited Treatment for primary biliary cholangitis
US11242326B2 (en) 2017-08-25 2022-02-08 The Board Of Trustees Of The University Of Illinois Multivalent ligand for myotonic dystrophy
US12201609B2 (en) 2018-12-18 2025-01-21 Zydus Lifesciences Limited Saroglitazar for the treatment of hepatocellular carcinoma
CN110372677B (zh) * 2019-07-25 2021-01-05 浙江海森药业股份有限公司 一种无溶剂法制备阿托伐他汀关键中间体l1的方法
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
US12201611B2 (en) 2020-07-24 2025-01-21 Zydus Lifesciences Limited Composition comprising high purity pyrrole derivative and method for preparation thereof
JP7765474B2 (ja) * 2020-12-03 2025-11-06 デルタ ４ ゲーエムベーハー 巣状分節性糸球体硬化症（ｆｓｇｓ）の治療における使用のためのサログリタザールおよびミリスチン酸

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU678974B2 (en) * 1992-07-03 1997-06-19 Smithkline Beecham Plc Heterocyclic compounds as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
GB9311644D0 (en) 1993-06-05 1993-07-21 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
BR9508468A (pt) 1994-07-29 1997-11-25 Smithkline Beecham Plc Composto processo para a preparação do mesmo composição farmacéutica processos para o tratamento e/ou profilaxia de hiperglicemia em um mamifero humano ou não humano e para o tratamento de hiperlípidemia hipertensão doença cardiovascular alguns distúrbios de alimentação o tratamento e/ou profilaxia de doença renal a prevenção revers o estabilização ou retardo da progressão de microalbuminuria em um mamifero humano ou não humano uso do composto e composto intermediário
EA000701B1 (ru) 1995-04-28 2000-02-28 Дайити Фармасьютикал Ко., Лтд. Пентациклическое соединение
HUP9601808A3 (en) 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
DE19607953A1 (de) 1996-03-01 1997-09-04 Kalle Nalo Gmbh Nach dem Aminoxidverfahren hergestellte Nahrungsmittelhüllen auf Cellulosebasis
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5889032A (en) 1996-05-06 1999-03-30 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
CN1230114A (zh) 1996-07-12 1999-09-29 史密丝克莱恩比彻姆有限公司 Leptine抵抗的新疗法
EP0897467B1 (de) 1996-12-24 2003-06-25 Daewoo Motor Co., Ltd. Abgasrückführventil für brennkraftmaschine
US6011036A (en) 1997-04-15 2000-01-04 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
CZ273997A3 (cs) 1997-09-02 1999-02-17 Rieter Elitex A.S. Spřádací ústrojí rotorového dopřádacího stroje
JP4462760B2 (ja) * 1997-09-11 2010-05-12 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー プロテアーゼインヒビターとして有用な４−ヒドロキシ−２−オキソ−ピラン誘導体の製法
EP0903343B1 (de) 1997-09-19 2003-05-28 SSP Co., Ltd. Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
EP1049684A1 (de) * 1997-10-27 2000-11-08 Dr. Reddy's Research Foundation Tricyclische verbindungen und ihre verwendung in der medizin; verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6265401B1 (en) 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
AU1887999A (en) 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
DE69902657T2 (de) 1998-05-05 2003-04-30 Sepracor Inc., Marlborough Hydroxyomeprazol-enthaltende zubereitungen und verwendungen
JP2002507543A (ja) 1998-05-27 2002-03-12 ドクター・レディーズ・リサーチ・ファウンデーション 二環系化合物、その製造方法およびそれらを含有する薬学的組成物
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
US6589969B1 (en) 1998-10-16 2003-07-08 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
EP1123269A1 (de) 1998-10-21 2001-08-16 Novo Nordisk A/S Neuartige verbindungen, ihre herstellung und ihre verwendung
DK1516874T3 (en) 1999-07-20 2015-11-23 Dow Agrosciences Llc Fungicidal heterocyclic aromatic amides and compositions, processes for their use and preparation thereof
US6312113B1 (en) * 1999-10-29 2001-11-06 Marconi Data Systems Inc. Ink circulation system
EP1250323B1 (de) * 2000-01-19 2014-01-01 Cadila Healthcare Limited Verbindungen mit hypolipidemischen und hypocholesterolemischen Wirkungen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
WO2002008188A1 (en) 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine

Also Published As

Publication number Publication date
US7323491B2 (en) 2008-01-29
WO2003009841A1 (en) 2003-02-06
EP1414439A1 (de) 2004-05-06
US20070238776A1 (en) 2007-10-11
US20040186099A1 (en) 2004-09-23
SI1414439T1 (sl) 2011-08-31
JP4313194B2 (ja) 2009-08-12
US7041837B2 (en) 2006-05-09
NO326698B1 (no) 2009-02-02
EA200400226A1 (ru) 2004-08-26
JP2009102423A (ja) 2009-05-14
US20080188402A1 (en) 2008-08-07
CO5390079A1 (es) 2004-04-30
MXPA04000758A (es) 2004-07-08
BR0211665A (pt) 2005-01-11
ES2366279T3 (es) 2011-10-18
KR100667710B1 (ko) 2007-01-12
PL224397B1 (pl) 2016-12-30
CN100450477C (zh) 2009-01-14
US8558009B2 (en) 2013-10-15
HRP20040138B1 (hr) 2016-12-02
DK1414439T3 (da) 2011-07-18
PL368289A1 (en) 2005-03-21
BR0211665B1 (pt) 2017-10-31
KR20040023685A (ko) 2004-03-18
ZA200400563B (en) 2004-10-29
EP1414439B1 (de) 2011-05-04
IL160042A (en) 2012-04-30
KR20060094545A (ko) 2006-08-29
BRPI0211665B8 (pt) 2021-05-25
HRP20040138A2 (en) 2005-02-28
CA2454863C (en) 2010-07-06
CN1558758A (zh) 2004-12-29
NZ545896A (en) 2008-06-30
EA006858B1 (ru) 2006-04-28
RS51837B (sr) 2012-02-29
AP1808A (en) 2007-12-18
US20030236254A1 (en) 2003-12-25
US8212057B2 (en) 2012-07-03
NO20040301L (no) 2004-03-24
UA76992C2 (uk) 2006-10-16
YU17404A (sh) 2006-08-17
US20110275669A1 (en) 2011-11-10
JP2005503367A (ja) 2005-02-03
CA2454863A1 (en) 2003-02-06
OA12702A (en) 2006-06-23
IL160042A0 (en) 2004-06-20
MY140057A (en) 2009-11-30
DE60239939D1 (de) 2011-06-16
AU2002355205B2 (en) 2004-11-18
PT1414439E (pt) 2011-07-27
AP2004002973A0 (en) 2004-03-31
NZ550375A (en) 2008-09-26
CY1111876T1 (el) 2015-11-04
US20030199498A1 (en) 2003-10-23
US6987123B2 (en) 2006-01-17
AR036347A1 (es) 2004-09-01
US8110598B2 (en) 2012-02-07

Similar Documents

Publication Publication Date Title
ATE507828T1 (de) Neue pyrrole mit hypolipidämischer und hypocholesterischer aktivität, herstellungsverfahren, diese enthaltende pharmazeutische zusammensetzungen und deren medizinische verwendung
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
BRPI0013391B8 (pt) uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
ATE309206T1 (de) Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen
EE05475B1 (et) Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon
ATE368041T1 (de) Neue pyrrolderivate als pharmazeutische mittel
ATE389019T1 (de) Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
DE60211532D1 (de) Pastöse zusammensetzung und diese enthaltende kosmetika
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE425979T1 (de) Neue substituierte imidazo-pyridinone und imidazo-pyridazinone, ihre herstellung und ihre verwendung als arzneimittel
DE50207522D1 (de) Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
ATE323713T1 (de) Neue heterocyclische fluorglykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05104B1 (et) Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
DE69816471D1 (de) Pyrimidinon verbindungen und diese enthaltende pharmazeutische zusammenstellungen
EE200200298A (et) Asendatud ftalotsüaniinid ja nende lähteühendid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja materjal
EE200200399A (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
EE04717B1 (et) Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine
ATE312828T1 (de) Acylaminothiazolderivate, deren herstellung und deren therapeutische verwendung
DE50113867D1 (de) Neue indolderivate und deren verwendung als arzneimittel
DE69724453D1 (de) Camptothecine analoga, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1414439

Country of ref document: EP